Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in the HVTN706/MOSAICO Study and Remain Without HIV
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2025-03-27
- Target Recruit Count
- 40
- Registration Number
- NCT06665646
- Locations
- π΅πͺ
Lima - San Marcos, Bella Vista, Peru
π΅πͺIquitos (ACSA CRS), Iquitos, Peru
π΅πͺLima - Via Libre, Lima, Peru
Phase 1 Study of Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
- Conditions
- Malaria
- Interventions
- Biological: P. vivax challenge agent derived from PvHMB-CCE001Biological: P. vivax challenge agent derived from PvHMB-CCE002
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-02-06
- Target Recruit Count
- 200
- Registration Number
- NCT06607003
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-11
- Target Recruit Count
- 60
- Registration Number
- NCT06585891
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR
- Conditions
- Tenofovir
- Interventions
- Drug: Oral F/TDF PillsDrug: TFV rectal douche
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-03-06
- Target Recruit Count
- 150
- Registration Number
- NCT06560684
- Locations
- πΊπΈ
Alabama CRS (Site ID# 31788), Birmingham, Alabama, United States
πΊπΈUCLA CARE Center CRS, Los Angeles, California, United States
πΊπΈHope Clinic CRS, Lawrenceville, Georgia, United States
A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV
- Conditions
- HIV Infections
- Interventions
- Biological: CH505M5 N197D mRNA-gp160
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-01-29
- Target Recruit Count
- 48
- Registration Number
- NCT06557785
- Locations
- πΊπΈ
Beth Israel Deaconess Medical Center (Site ID: 32077), Boston, Massachusetts, United States
πΊπΈColumbia P&S (Site ID: 30329), New York, New York, United States
πΊπΈNew York Blood Center (Site ID: 31801), New York, New York, United States
The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2025-05-16
- Target Recruit Count
- 400
- Registration Number
- NCT06551506
- Locations
- πΊπΈ
Emory University School of Medicine, Atlanta, Georgia, United States
πΊπΈUniversity of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States
πΊπΈNew York University School of Medicine - Langone Medical Center - Vaccine Center, New York, New York, United States
Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age
- Conditions
- Human Parainfluenza Virus Type 3Human Metapneumovirus
- Interventions
- Biological: B/HPIV3/HMPV-PreF-A vaccineBiological: B/HPIV3/HMPV-F-B365 vaccineDrug: Placebo
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-12
- Target Recruit Count
- 25
- Registration Number
- NCT06546423
- Locations
- πΊπΈ
University of Rochester Medical Center, Rochester, New York, United States
πΊπΈCIR South, Columbia, Maryland, United States
πΊπΈVanderbilt University Medical Center, Nashville, Tennessee, United States
Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2025-01-30
- Target Recruit Count
- 48
- Registration Number
- NCT06517693
- Locations
- π΅π·
Site 5129, IMPAACT/Gamma Project/UPR Pediatric HIV/AIDS Research, San Juan, Puerto Rico
πΊπΈSite 5030, Emory University School of Medicine, Atlanta, Georgia, United States
πΊπΈSite 5112, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
The Tatelo Plus Study
- Conditions
- HIVHIV Infections
- Interventions
- Other: Analytic Treatment InterruptionDrug: ART Regimen prior to enrolling in Step 1aDrug: ART Regimen prior to enrolling in Step 1b
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-11-20
- Target Recruit Count
- 41
- Registration Number
- NCT06508749
- Locations
- π§πΌ
Francistown CRS (CRS #31891), Francistown, Botswana
π§πΌBotswana Harvard Health Partnership CRS (CRS #31833), Gaborone, Botswana
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: ShA9 Topical GelDrug: Placebo (Vehicle) Topical Gel
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2025-05-11
- Target Recruit Count
- 86
- Registration Number
- NCT06504160
- Locations
- πΊπΈ
University of California, San Diego: Dermatology Clinical Trials Unit, San Diego, California, United States
πΊπΈNational Jewish Health: Division of Pediatric Allergy and Clinical Immunology, Denver, Colorado, United States
πΊπΈNorthwestern University Feinberg School of Medicine: Department of Dermatology, Chicago, Illinois, United States